bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract LB-70: BRCA1 impacts ovarian cancer cell migration through modulating Pfn1 expression
Authors: Gau David M. , Lesnock Jamie , Krivak Thomas , Edwards Robert , Roy Partha 
Published: May 2015

Abstract
Functional loss of BRCA1 has been implicated in genomic instability and cancer progression. A recent study demonstrated that BRCA1 plays a role in cancer cell migration. Using a random cell motility assay, we showed that BRCA1 promotes ovarian cancer cell migration. A proteomics study of BRCA1 +/- cell lines and tissues identified Profilin1 (Pfn1) as one of the differentially expressed proteins. This was further confirmed by Western blot and IHC analyses with tissue samples and cell lines. Pfn1 is an actin cytoskeleton-associated protein which promotes breast cancer cell motility/invasion and dissemination when downregulated. To further study whether BRCA1 impacts cell migration through Pfn1, Pfn1 was silenced which revealed enhanced motility in multiple BRCA1-WT ovarian cancer cell lines. Furthermore, overexpression of Pfn1 in BRCA1 cell lines reduced random motility which further implicates the importance of Pfn1 in ovarian cancer motility. This is the first evaluation of both motility and the functional role of Pfn1 in ovarian cancer cells. While BRCA1 has been extensively studied in the context of DNA repair, there is emerging evidence that BRCA1 proteins may play a role in cell migration. The increased motility seen in wild-type cells compared to BRCA1-mutated cells may portend increased metastatic potential in wild-type cancers. Our findings demonstrate that 1) BRCA1 positively influences ovarian cancer cell motility, and 2) BRCA1 status determines Pfn1's role in ovarian cancer cell motility suggesting a possible novel mechanism association between Pfn1 and BRCA1 and ovarian cancer cell motility. Future studies should explore whether Pfn1 downregulation enhances the metastatic potential of ovarian cancer cells with intact BRCA1 function and whether Pfn1 may serve as a possible therapeutic target.
Citation Format: David M. Gau, Jamie Lesnock, Thomas Krivak, Robert Edwards, Partha Roy. BRCA1 impacts ovarian cancer cell migration through modulating Pfn1 expression. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-70. doi:10.1158/1538-7445.AM2014-LB-70
Abstract SY04-04: Vitamin D receptor stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy
Authors: Evans Ronald M. 
Published: May 2015

Abstract
The poor clinical outcome in pancreatic ductal adenocarcinoma (PDA) is attributed to intrinsic chemoresistance and a growth-permissive tumor microenvironment. Conversion of quiescent to activated pancreatic stellate cells (PSCs) is thought to drive the severe stromal reaction that characterizes PDA. Here we reveal that the vitamin D receptor (VDR) is expressed in activated human pancreatic tumor stroma as well as in in vivo models of pancreatitis, a known risk factor for PDA. Notably, treatment with the VDR ligand calcipotriol markedly reduced inflammation and fibrosis during pancreatitis and a more pronounced form of the disease developed in VDR knockout mice. We show that VDR acts as a master transcriptional regulator of PSCs to reprise the quiescent state such that ligand-induced stromal remodeling increased intratumoral gemcitabine levels 5-fold and reduced tumor volume. This work describes a molecular strategy through which epigenomic reprogramming of pancreatic tumor stroma rescues/fosters a robust chemotherapeutic response and advocates a reevaluation of vitamin D therapy for PDA.
Citation Format: Ronald M. Evans. Vitamin D receptor stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr SY04-04. doi:10.1158/1538-7445.AM2014-SY04-04
Abstract SY21-02: Extracellular matrix density, alignment, and tumor progression
Authors: Keely Patricia J. 
Published: May 2015

Abstract
An increase in the mammographic density of breast tissue is correlated to a four to six-fold increased risk of developing breast carcinoma, making it the single biggest risk factor for breast carcinoma. Increased breast density is associated with a significant increase in the deposition of ECM components, most notably collagen, which leads to an increase in matrix stiffness. In a mouse model of increased collagen deposition, we find that mammary tumor incidence, invasion, and metastasis increased three-fold. Mammary tumors arising in FAK-/- mammary glands were non-invasive and non-metastatic. Gene expression profiling of these tumors identified a metastasis signature regulated by FAK, and further identify novel mechanisms and signaling pathways governing invasion into collagen matrices.
Using state-of-the-art non-linear optical imaging techniques (FLIM and SHG), we have imaged collagen and cells at the tumor-stromal boundary in live, unfixed mammary tumors. We find that during tumor progression, the structure and alignment of collagen fibers is altered, such that the perpendicular realignment of collagen fibers is completely coincident with areas of local invasion. A recent analysis of 207 human samples demonstrates that the presence of perpendicular aligned collagen was a novel significant and independent prognostic indicator of poor patient survival, with a risk factor of 4.3. To determine whether fibril alignment facilitates invasion, we engineered aligned matrices, and found that human breast carcinoma cells preferentially invaded along perpendicularly aligned vs. random or parallel collagen fibers. Our results demonstrate collagen fibers serve as a highway to facilitate local invasion, and promote distal metastasis.
Citation Format: Patricia J. Keely. Extracellular matrix density, alignment, and tumor progression. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr SY21-02. doi:10.1158/1538-7445.AM2014-SY21-02
Abstract A08: Investigating tumor vasculature development and the effects of OXi4503 by non-invasive photoacoustic imaging
Authors: Johnson Sean Peter , Ogunlade Ollie , Zhang Edward , Lythgoe Mark , Beard Paul , Pedley Rosamund Barbara 
Published: May 2015

Abstract
Vasculature-targeted cancer therapies, such as vascular disrupting or anti-angiogenic agents, interact directly with tumor blood vessels. Direct longitudinal assessment of vascular response, as opposed to indirect measures of tumor volume, would aid clinical translation for these targeted therapies, but novel treatment strategies require adequate biomarkers of response.
OXi4503 (Combretastatin-A1 phosphate, CA1P) is a vascular disrupting agent (VDA) known to have significant antitumor effects against a wide range of pre-clinical human tumor model systems, and in the clinic. OXi4503 causes disruption of the central tumor vasculature within an hour of administration, followed by thrombosis and vessel occlusion, resulting in massive central tumor necrosis 24 hours after treatment but leaving a thin viable rim of tumor cells.
Photoacoustic imaging (PAI) is a novel non-ionising and non-invasive technique, that provides 3D images of the vascular microenvironment with high spatial resolution. Structural information of blood vessel location, and potentially functional data as well, can therefore be obtained in a longitudinal manner. It is thus ideally suited to assess preclinical models of subcutaneous tumors with regard to vascular targeted therapies. We have used PAI to investigate the development of tumor blood vessels, and the effects of OXi4503 (40mg/kg) on the vasculature of 2 human colorectal xenografts grown in nude mice.
Results: The human colorectal tumor cell lines SW1222 and LS174T were established as subcutaneous models in nude mice, by the injection of 5X106 tumor cells.
Using PAI we were able to:
Determine the extent and pattern of tumor vascularization, non-invasively, over time
Differentiate between the pathophysiologies of different tumor types
Follow the response to vascular targeted therapy
Determine the length of time to tumor regrowth following therapy
Conclusion: The data suggest that PAI could prove invaluable in providing imaging biomarkers of response to treatment for vascular targeted therapies, with potential for clinical translation.
Citation Format: Sean Peter Johnson, Ollie Ogunlade, Edward Zhang, Mark Lythgoe, Paul Beard, Rosamund Barbara Pedley. Investigating tumor vasculature development and the effects of OXi4503 by non-invasive photoacoustic imaging. [abstract]. In: Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; 2014 Feb 26-Mar 1; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(1 Suppl):Abstract nr A08. doi:10.1158/1538-7445.CHTME14-A08
Abstract A65: Heterogeneous response of H460 non-small lung carcinoma cells to CPI-613, a novel compound that selectively alters tumor energy metabolism
Authors: Perera Candida N. , Rodriguez Robert , Shorr Robert 
Published: May 2015

Abstract
Lung cancer is the leading cause of cancer-related death. The high prevalence coupled with the high death rate and current lack of effective therapy against this type of cancer have spurred research on the characteristics of tumor cells and the search for novel strategies to prevent and treat lung cancer. The relationship between the degree of heterogeneity of tumor cells vs. the tumor cells sensitivity to anti-cancer agents may reflect the presence of cancer causing stem cells. The H460 non-small cell lung cancer cell line has been documented to have a great degree of heterogeneity with various degrees of responsiveness to the anti-cancer drug paclitaxel. The objective of this investigation was to assess the phenotypic heterogeneity of the H460 cell line following treatment with CPI-613. CPI-613 is a novel anti-cancer agent that selectively targets the altered form of mitochondrial energy metabolism utilized by tumor cells, that illicit changes in mitochondrial enzyme activities and cellular redox status leading to apoptosis, necrosis, and/or autophagia of tumor cells, without affecting normal cells. Different populations of H460 cells were generated following treatment of these cells with 1-2 rounds of CPI-613. The IC50 for the sub-population of H460 cells was approximately twice higher than that of parent H460 population (52±8 vs. 29±3 μM), suggesting the H460 cell line have CPI-613-sensitive and less sensitive sub-populations. Gene expression profiling revealed a difference in the metabolic and signaling pathways altered by CPI-613 among the different sub-populations. The cellular morphology observed under the microscope and up-regulation of SNAI2 and mesenchymal markers suggested that the sub-population consisted of cells with the epithelial-mesenchymal transition (EMT) phenotype. Recent evidence suggests that cells that undergo EMT gain stem cell-like properties, thus giving rise to cancer stem cells. We were able to demonstrate that treatment of parent H460 cells with CPI-613 at 50 μM for 24 hrs eliminated the sensitive population and treatment for 48 hrs was able to completely eliminate the resistant population containing cells with stem cell-like properties.
Citation Format: Candida N. Perera, Robert Rodriguez, Robert Shorr. Heterogeneous response of H460 non-small lung carcinoma cells to CPI-613, a novel compound that selectively alters tumor energy metabolism. [abstract]. In: Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; 2014 Feb 26-Mar 1; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(1 Suppl):Abstract nr A65. doi:10.1158/1538-7445.CHTME14-A65
Abstract B10: LFA-1/ICAM-1 interaction switches on an orchestrated prometastatic microenvironmental shift during experimental liver metastasis of colon C26 cancer cells.
Authors: Benedicto Aitor , Marquez Joana , Olaso Elvira , Arteta Beatriz 
Published: May 2015

Abstract
Intercellular adhesion molecule (ICAM)-1 is the main counter-receptor for the lymphocyte function associated antigen (LFA)-1. However, the role this interaction plays during liver metastasis of colorectal cancer cells and its underlying mechanisms remain unclear. Previously, we showed that mannose receptor (ManR) stimulation on liver sinusoidal endothelial cells (LSECs) resulted in a reduced cytotoxic potential of liver infiltrating lymphocytes (LIL) towards C26 murine colon carcinoma cells.
Using ICAM-1 specific siRNAs in vivo, we aimed to study the role of hepatic ICAM-1 in the prometastatic shift of the liver microenvironment. Livers of control and silenced mice, 24 hours and 14 days after C26 cell inoculation, were compared for: percentage of detained C26 cells, number and volume of metastatic foci, levels of recruited immune, myofibroblastic and inflammatory cells and whole liver expression of pro-inflammatory genes.
Detained cancer cells and metastatic foci number were reduced in silenced mice compared to controls, along with a decrease in myeloid suppressor cells and recruited macrophages and myofibroblasts. On the contrary, significant higher numbers of lymphocytic cells were observed in mice with reduced ICAM-1. Finally, silencing of ICAM1 resulted in altered total liver mRNA levels of proinflammatory factors in the tumor-bearing mice.
Therefore, an orchestrated prometastatic program might be switched on in the liver microenvironment by LFA-1/ICAM-1 interaction which, in turn, could lead not only to a reduced antitumor citotoxicity but, also, to activation of the stromal compartment favoring tumor progression, and, opening liver's doors to tumor cells to aggressively metastasize. Based on these results, LFA-1/ICAM-1 interaction arises as a potential therapeutic target in cancer treatment.
Citation Format: Aitor Benedicto, Joana Marquez, Elvira Olaso, Beatriz Arteta. LFA-1/ICAM-1 interaction switches on an orchestrated prometastatic microenvironmental shift during experimental liver metastasis of colon C26 cancer cells.. [abstract]. In: Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; 2014 Feb 26-Mar 1; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(1 Suppl):Abstract nr B10. doi:10.1158/1538-7445.CHTME14-B10
Abstract B16: Progastrin activates colon fibroblasts and participates to the dialogue between tumor epithelial cells and stromal fibroblasts in colorectal cancer
Authors: Fénié Nicolas , Bertrand Claudine , Lacombe Aurélien , Roche Serge , Bousquet Corinne , Gouazé-Andersson Valérie , Toulas Christine , Moyal Elizabeth , Ferrand Audrey 
Published: May 2015

Abstract
Colorectal cancer (CRC) represents the second leading cause of cancer-related death worldwide. One of the main reasons for this high mortality rate is because CRC develops into invasive lesions with high metastasis potential. The cancer-associated fibroblasts (CAFs) present in the tumour reactive stroma promote epithelial cancer cell motility and aggressiveness. However, whereas the role of tumour-stroma crosstalks in cancer progression is increasingly documented, how “normal” resident fibroblasts are converted into pro-invasive CAFs and how CAFs participate to the epithelial-stroma dialogue remains an open question. Precursor of the hormone gastrin, progastrin, now established as a growth factor for colon cells, is detected in colorectal polyps and tumours while it is absent in healthy colon.
Using immunohistochemical and biochemical approaches we found that progastrin induces the expression of fibroblast activation markers (alphaSMA, FAPalpha) in the normal colon mucosa of progastrin-overexpressing mice as well as in the human colon fibroblast cell line CCD18Co. To investigate the role of progastrin-induced fibroblast activation, we compared the migration of colon epithelial cancer cells expressing or not the hormone in presence or absence of fibroblasts in Boyden chamber. Progastrin-expressing epithelial cells have increased migration capacities in presence of fibroblasts while not difference between the two epithelial cell lines was observed in absence of fibroblasts. Moreover, we identified the implication of different chemokines in this process.
Thus, here we demonstrate that progastrin, secreted by tumour epithelial cells, contributes to the activation of the fibroblasts present in the cancer-associated stroma and participates to the epithelial-stroma dialogue.
Citation Format: Nicolas Fénié, Claudine Bertrand, Aurélien Lacombe, Serge Roche, Corinne Bousquet, Valérie Gouazé-Andersson, Christine Toulas, Elizabeth Moyal, Audrey Ferrand. Progastrin activates colon fibroblasts and participates to the dialogue between tumor epithelial cells and stromal fibroblasts in colorectal cancer. [abstract]. In: Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; 2014 Feb 26-Mar 1; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(1 Suppl):Abstract nr B16. doi:10.1158/1538-7445.CHTME14-B16
Deficiency in Melanocortin 1 Receptor Signaling Predisposes to Vascular Endothelial Dysfunction and Increased Arterial Stiffness in Mice and Humans
Authors: Rinne Petteri , Ahola-Olli Ari , Nuutinen Salla , Koskinen Emilia , Kaipio Katja , Eerola Kim , Juonala Markus , Kähönen Mika , Lehtimäki Terho , Raitakari Olli T. , Savontaus Eriika 
Published: May 2015

Objective—
The melanocortin 1 receptor (MC1-R) is expressed by vascular endothelial cells and shown to enhance nitric oxide (NO) availability and vasodilator function on pharmacological stimulation. However, the physiological role of MC1-R in the endothelium and its contribution to vascular homeostasis remain unresolved. We investigated whether a lack of functional MC1-R signaling carries a phenotype with predisposition to vascular abnormalities.

Approach and Results—

Recessive yellow mice (MC1R
e/e
), deficient in MC1-R signaling, and their wild-type littermates were studied for morphology and functional characteristics of the aorta. MC1R
e/e
mice showed increased collagen deposition and arterial stiffness accompanied by an elevation in pulse pressure. Contractile capacity and NO-dependent vasodilatation were impaired in the aorta of MC1R
e/e
mice supported by findings of decreased NO availability. These mice also displayed elevated levels of systemic and local cytokines. Exposing the mice to high-sodium diet or acute endotoxemia revealed increased susceptibility to inflammation-driven vascular dysfunction. Finally, we investigated whether a similar phenotype can be found in healthy human subjects carrying variant
MC1-R
alleles known to attenuate receptor function. In a longitudinal analysis of 2001 subjects with genotype and ultrasound data (The Cardiovascular Risk in Young Finns Study), weak MC1-R function was associated with lower flow-mediated dilatation response of the brachial artery and increased carotid artery stiffness.

Conclusions—
The present study demonstrates that deficiency in MC1-R signaling is associated with increased arterial stiffness and impairment in endothelium-dependent vasodilatation, suggesting a physiological role for MC1-R in the regulation of arterial tone.
Choline Transporter-Like Protein-2
Authors: Bayat Behnaz , Tjahjono Yudy , Berghöfer Heike , Werth Silke , Deckmyn Hans , De Meyer Simon F. , Sachs Ulrich J. , Santoso Sentot 
Published: May 2015

Objective—
In contrast to other antibodies involved in transfusion-related acute lung injury, anti–HNA-3a antibodies are incapable of inducing direct neutrophil activation and seem to interact with endothelial cells (ECs) primarily. In animal studies, anti–HNA-3a-mediated transfusion-related acute lung injury could be precipitated in the absence of neutrophils, but was stronger when neutrophils were present. In a different context the target protein of these antibodies, choline transporter-like protein-2 (CTL-2), was reported to interact with a protein of the inner ear carrying 2 von Willebrand factor (VWF) A-domains. These observations prompted us to investigate whether VWF might be involved in anti–HNA-3a-mediated neutrophil activation, and whether signaling via CD11b/CD18 is involved, as in various other experimental settings.

Approach and Results—
Cell adhesion demonstrated specific binding of CTL-2 to VWF. Immunoprecipitation analysis of CTL-2/CD11b/CD18 coexpressing cells indicated that anti–HNA-3a colocalizes CTL-2 and CD11b/CD18 when VWF is present. Functional studies revealed that anti–HNA-3a-mediated neutrophil agglutination is an active, protein kinase C-dependent and partially Fc-dependent process. Agglutination and the production of reactive oxygen species seem to require the formation of a trimolecular complex between the target antigen (CTL-2), CD11b/CD18 and VWF. In line with these observations, anti–HNA-3a induced less severe transfusion-related acute lung injury and less neutrophil recruitment to the alveolar space in VWF knockout mice.

Conclusions—
We introduce CTL-2 as a new binding partner for VWF. Interaction of neutrophils with VWF via CTL-2 allows anti–HNA-3a to induce signal transduction via CD11b/CD18, which leads to neutrophil activation and agglutination. In transfusion-related acute lung injury, this mechanism may further aggravate endothelial leakage.
Effects of Postinfarct Myelin-Associated Glycoprotein Antibody Treatment on Motor Recovery and Motor Map Plasticity in Squirrel Monkeys
Authors: Barbay Scott , Plautz Erik J. , Zoubina Elena , Frost Shawn B. , Cramer Steven C. , Nudo Randolph J. 
Published: May 2015

Background and Purpose—
New insights into the brain’s ability to reorganize after injury are beginning to suggest novel restorative therapy targets. Potential therapies include pharmacological agents designed to promote axonal growth. The purpose of this study was to test the efficacy of one such drug, GSK249320, a monoclonal antibody that blocks the axon outgrowth inhibition molecule, myelin-associated glycoprotein, to facilitate recovery of motor skills in a nonhuman primate model of ischemic cortical damage.

Methods—
Using a between-groups repeated-measures design, squirrel monkeys were randomized to 1 of 2 groups: an experimental group received intravenous GSK249320 beginning 24 hours after an ischemic infarct in motor cortex with repeated dosages given at 1-week intervals for 6 weeks and a control group received only the vehicle at matched time periods. The primary end point was a motor performance index based on a distal forelimb reach-and-retrieval task. Neurophysiological mapping techniques were used to determine changes in spared motor representations.

Results—
All monkeys recovered to baseline motor performance levels by postinfarct day 16. Functional recovery in the experimental group was significantly facilitated on the primary end point, albeit using slower movements. At 7 weeks post infarct, motor maps in the spared ventral premotor cortex in the experimental group decreased in area compared with the control group.

Conclusions—
GSK249320, initiated 24 hours after a focal cortical ischemic infarct, facilitated functional recovery. Together with the neurophysiological data, these results suggest that GSK249320 has a substantial biological effect on spared cortical tissue. However, its mechanisms of action may be widespread and not strictly limited to peri-infarct cortex and nearby premotor areas.